UroGen Pharma Quarterly Balance Sheets Chart
Quarterly
|
Annual
UroGen Pharma Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||||||
| cash and cash equivalents | 92,904,000 | 104,033,000 | 171,987,000 | 124,916,000 | 219,972,000 | 131,439,000 | 95,002,000 | 119,305,000 | 20,127,000 | 36,540,000 | 55,408,000 | 28,686,000 | 80,690,000 | 105,379,000 | 44,360,000 | 55,337,000 | 63,322,000 | 40,492,000 | 52,864,000 | 24,565,000 | 36,350,000 | 26,468,000 | 49,688,000 | 66,147,000 | 90,424,000 | 246,692,000 | 101,318,000 | 36,999,000 |
| marketable securities | 64,050,000 | 91,857,000 | 64,698,000 | 124,659,000 | 21,106,000 | 32,606,000 | 41,966,000 | 28,114,000 | 27,174,000 | 28,514,000 | 44,556,000 | 67,225,000 | 31,048,000 | 31,065,000 | 44,779,000 | 50,872,000 | 57,710,000 | 35,417,000 | 49,154,000 | 95,058,000 | 88,773,000 | 92,623,000 | 97,389,000 | 92,046,000 | 98,739,000 | |||
| restricted cash | 1,082,000 | 1,076,000 | 1,076,000 | 1,073,000 | 825,000 | 823,000 | 821,000 | 817,000 | 816,000 | 814,000 | 813,000 | 812,000 | 811,000 | 550,000 | 1,226,000 | 1,226,000 | 1,225,000 | 1,225,000 | 1,226,000 | 1,224,000 | 1,224,000 | 1,223,000 | 523,000 | |||||
| accounts receivable | 19,649,000 | 19,638,000 | 20,302,000 | 22,802,000 | 17,415,000 | 14,158,000 | 15,443,000 | 12,847,000 | 15,505,000 | 12,493,000 | 12,704,000 | 9,429,000 | 11,595,000 | 9,499,000 | 11,717,000 | 7,784,000 | 9,512,000 | 6,301,000 | 7,047,000 | 2,810,000 | 402,000 | |||||||
| inventories | 7,128,000 | 7,590,000 | 9,227,000 | 7,594,000 | 7,442,000 | 7,243,000 | 5,673,000 | 5,002,000 | 4,988,000 | 5,466,000 | 4,325,000 | 4,862,000 | 5,047,000 | 4,756,000 | 4,832,000 | 3,808,000 | 3,421,000 | |||||||||||
| prepaid expenses and other current assets | 12,055,000 | 12,983,000 | 8,845,000 | 14,053,000 | 12,208,000 | 10,491,000 | 10,281,000 | 16,038,000 | 12,723,000 | 12,146,000 | 11,101,000 | 10,580,000 | 10,433,000 | 6,316,000 | 3,364,000 | 4,335,000 | 2,069,000 | 1,552,000 | 1,034,000 | 1,160,000 | 1,724,000 | 1,196,000 | 672,000 | 958,000 | ||||
| total current assets | 196,868,000 | 237,177,000 | 276,135,000 | 295,097,000 | 278,968,000 | 196,760,000 | 169,186,000 | 182,123,000 | 81,333,000 | 95,973,000 | 128,907,000 | 121,594,000 | 139,624,000 | 160,524,000 | 114,390,000 | 125,140,000 | 140,498,000 | 93,082,000 | 115,619,000 | 129,338,000 | 129,943,000 | 121,866,000 | 148,634,000 | 159,876,000 | 191,194,000 | 248,295,000 | 102,243,000 | 74,472,000 |
| non-current assets: | ||||||||||||||||||||||||||||
| property and equipment | 688,000 | 627,000 | 655,000 | 608,000 | 580,000 | 566,000 | 689,000 | 823,000 | 910,000 | 1,103,000 | 1,297,000 | 1,519,000 | 1,605,000 | 1,777,000 | 1,967,000 | 1,978,000 | 2,001,000 | 2,142,000 | 2,046,000 | 1,725,000 | 1,401,000 | 991,000 | 977,000 | 893,000 | 909,000 | 929,000 | 948,000 | 805,000 |
| restricted deposit | 177,000 | 176,000 | 176,000 | 175,000 | 175,000 | 226,000 | 225,000 | 225,000 | 224,000 | 224,000 | 223,000 | 223,000 | 223,000 | 223,000 | 223,000 | 223,000 | 223,000 | 223,000 | 223,000 | 223,000 | 223,000 | 223,000 | 223,000 | 523,000 | 307,000 | 407,000 | 253,000 | 198,000 |
| right of use assets | 5,551,000 | 4,753,000 | 1,052,000 | 1,250,000 | 1,443,000 | 1,905,000 | 2,107,000 | 2,329,000 | 2,452,000 | 2,666,000 | 2,116,000 | |||||||||||||||||
| other non-current assets | 801,000 | 371,000 | 589,000 | 370,000 | 673,000 | 1,098,000 | 2,038,000 | 2,050,000 | 2,817,000 | 3,160,000 | 2,740,000 | 2,471,000 | 1,900,000 | 1,572,000 | 1,311,000 | 1,773,000 | 1,103,000 | 66,000 | 66,000 | 55,000 | 279,000 | 264,000 | 2,423,000 | 2,557,000 | 2,777,000 | 317,000 | 244,000 | |
| total assets | 208,717,000 | 247,618,000 | 285,711,000 | 301,943,000 | 281,849,000 | 200,574,000 | 178,311,000 | 193,633,000 | 95,361,000 | 112,954,000 | 135,619,000 | 128,473,000 | 146,141,000 | 165,715,000 | 119,746,000 | 134,603,000 | 153,768,000 | 97,414,000 | 122,005,000 | 139,893,000 | 161,077,000 | 166,929,000 | 202,388,000 | 226,753,000 | 238,566,000 | 252,052,000 | 103,559,000 | 75,550,000 |
| liabilities and shareholders' deficit | ||||||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||||||
| accounts payable and accrued expenses | 30,962,000 | 30,322,000 | 27,431,000 | 19,685,000 | 23,754,000 | 18,158,000 | 16,538,000 | 14,083,000 | 16,403,000 | 17,130,000 | 12,383,000 | 9,356,000 | 8,647,000 | 12,102,000 | 10,558,000 | 10,023,000 | 8,492,000 | 9,203,000 | 8,500,000 | 11,186,000 | 7,880,000 | 7,071,000 | 5,942,000 | 8,540,000 | 4,435,000 | |||
| employee related accrued expenses | 11,646,000 | 6,967,000 | 10,570,000 | 9,029,000 | 6,849,000 | 4,985,000 | 10,814,000 | 8,152,000 | 6,721,000 | 4,919,000 | 8,257,000 | 6,625,000 | 6,428,000 | 6,948,000 | 4,712,000 | 9,554,000 | 7,791,000 | 5,744,000 | 4,075,000 | 6,711,000 | 5,082,000 | 3,706,000 | 3,334,000 | 4,925,000 | 1,950,000 | |||
| other current liabilities | 4,940,000 | 4,711,000 | 7,948,000 | 4,073,000 | 3,620,000 | 3,197,000 | 3,860,000 | 3,553,000 | 3,641,000 | 3,185,000 | 3,276,000 | 3,018,000 | 2,965,000 | 4,009,000 | 3,330,000 | 2,268,000 | 1,941,000 | 1,735,000 | 1,859,000 | 1,335,000 | 1,476,000 | 1,632,000 | 1,585,000 | 1,126,000 | 1,067,000 | 1,001,000 | ||
| total current liabilities: | 47,548,000 | 42,000,000 | 45,949,000 | 32,787,000 | 34,223,000 | 26,340,000 | 31,212,000 | 25,788,000 | 26,765,000 | 25,234,000 | 23,916,000 | 18,999,000 | 18,040,000 | 19,091,000 | 22,380,000 | 19,806,000 | 19,056,000 | 17,005,000 | 21,436,000 | 17,618,000 | ||||||||
| non-current liabilities: | ||||||||||||||||||||||||||||
| prepaid forward obligation | 124,833,000 | 123,336,000 | 121,387,000 | 118,526,000 | 115,880,000 | 112,947,000 | 109,722,000 | 107,276,000 | 104,507,000 | 101,912,000 | 98,923,000 | 96,192,000 | 93,461,000 | 89,782,000 | 85,713,000 | 79,927,000 | 74,802,000 | |||||||||||
| long-term debt | 122,508,000 | 122,108,000 | 121,734,000 | 121,709,000 | 97,813,000 | 97,590,000 | 98,551,000 | 98,518,000 | 98,296,000 | 97,941,000 | 97,537,000 | 71,870,000 | 71,196,000 | 70,797,000 | ||||||||||||||
| long-term lease liabilities | 3,413,000 | 2,841,000 | 1,653,000 | 212,000 | 425,000 | 637,000 | 844,000 | 1,026,000 | 1,209,000 | 1,403,000 | 1,586,000 | 1,856,000 | 1,515,000 | 398,000 | ||||||||||||||
| uncertain tax positions liability | 3,791,000 | 3,791,000 | 3,791,000 | 3,194,000 | 3,194,000 | 3,194,000 | 3,194,000 | 3,018,000 | 3,018,000 | 3,018,000 | 3,018,000 | 2,842,000 | 2,842,000 | 2,842,000 | 2,842,000 | 2,717,000 | 2,717,000 | 2,717,000 | 2,717,000 | |||||||||
| total liabilities | 302,093,000 | 294,076,000 | 294,514,000 | 276,428,000 | 251,535,000 | 240,708,000 | 243,523,000 | 235,626,000 | 233,795,000 | 229,508,000 | 224,980,000 | 191,759,000 | 187,054,000 | 182,789,000 | 111,333,000 | 103,066,000 | 97,497,000 | 20,923,000 | 25,650,000 | 19,366,000 | 18,417,000 | 16,475,000 | 22,086,000 | 15,837,000 | 13,787,000 | 12,461,000 | 13,465,000 | 7,035,000 |
| commitments and contingencies | ||||||||||||||||||||||||||||
| shareholders' deficit: | ||||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value, 100,000,000 shares authorized at june 30, 2025 and december 31, 2024; 46,199,134 and 42,231,746 shares issued and outstanding as of june 30, 2025 and december 31, 2024, respectively | 126,000 | |||||||||||||||||||||||||||
| additional paid-in capital | 806,497,000 | 803,467,000 | 797,248,000 | 793,874,000 | 775,270,000 | 671,438,000 | 614,035,000 | 611,389,000 | 493,109,000 | 490,744,000 | 487,787,000 | 485,041,000 | 481,485,000 | 478,646,000 | 475,698,000 | 470,341,000 | 464,823,000 | 458,723,000 | 452,525,000 | 445,950,000 | 438,999,000 | 415,895,000 | 407,986,000 | 399,600,000 | 391,233,000 | 383,850,000 | 212,921,000 | 115,692,000 |
| accumulated deficit | -900,005,000 | -850,065,000 | -806,222,000 | -768,710,000 | -745,037,000 | -711,634,000 | -679,348,000 | -653,332,000 | -631,453,000 | -607,317,000 | -577,104,000 | -548,235,000 | -522,404,000 | -495,713,000 | -467,321,000 | -438,869,000 | -408,658,000 | -382,436,000 | -356,501,000 | -325,975,000 | -297,159,000 | -265,810,000 | -228,017,000 | -189,044,000 | -166,792,000 | -144,315,000 | -122,871,000 | -47,214,000 |
| accumulated other comprehensive income | 6,000 | 14,000 | 56,000 | 236,000 | -31,000 | 12,000 | -69,000 | -25,000 | 4,000 | 45,000 | 143,000 | 271,000 | 492,000 | 760,000 | 311,000 | 276,000 | 303,000 | 281,000 | ||||||||||
| total shareholders' deficit | -93,376,000 | -46,458,000 | -8,803,000 | -40,134,000 | -65,212,000 | -41,993,000 | -138,434,000 | -116,554,000 | ||||||||||||||||||||
| total liabilities and shareholders' deficit | 208,717,000 | 247,618,000 | 285,711,000 | 200,574,000 | 178,311,000 | 193,633,000 | 95,361,000 | 112,954,000 | ||||||||||||||||||||
| ordinary shares, nis 0.01 par value, 100,000,000 shares authorized at march 31, 2025 and december 31, 2024; 46,101,785 and 42,231,746 shares issued and outstanding as of march 31, 2025 and december 31, 2024, respectively | 126,000 | |||||||||||||||||||||||||||
| right-of-use assets | 3,134,000 | 1,671,000 | ||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value; 100,000,000 shares authorized at december 31, 2024 and 2023; 42,231,746 and 32,490,119 shares issued and outstanding as of december 31, 2024 and 2023, respectively | 115,000 | |||||||||||||||||||||||||||
| liabilities and shareholders' equity | ||||||||||||||||||||||||||||
| shareholders' equity | ||||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value, 100,000,000 shares authorized at september 30, 2024 and december 31, 2023; 42,190,815 and 32,490,119 shares issued and outstanding as of september 30, 2024 and december 31, 2023, respectively | 115,000 | |||||||||||||||||||||||||||
| total shareholders' equity | 25,515,000 | 30,314,000 | -63,286,000 | -40,913,000 | -17,074,000 | 8,413,000 | 31,537,000 | 56,271,000 | 76,491,000 | 96,355,000 | ||||||||||||||||||
| total liabilities and shareholders' equity | 301,943,000 | 281,849,000 | 128,473,000 | 146,141,000 | 165,715,000 | 119,746,000 | 134,603,000 | 153,768,000 | 97,414,000 | 122,005,000 | ||||||||||||||||||
| ordinary shares, nis 0.01 par value, 100,000,000 shares authorized at june 30, 2024 and december 31, 2023; 41,169,954 and 32,490,119 shares issued and outstanding as of june 30, 2024 and december 31, 2023, respectively | 112,000 | |||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value, 100,000,000 shares authorized at march 31, 2024 and december 31, 2023; 36,127,687 and 32,490,119 shares issued and outstanding as of march 31, 2024 and december 31, 2023, respectively | 99,000 | |||||||||||||||||||||||||||
| accumulated other comprehensive loss | -37,000 | -134,000 | -154,000 | -45,000 | -107,000 | -155,000 | -56,000 | |||||||||||||||||||||
| ordinary shares, nis 0.01 par value; 100,000,000 shares authorized at december 31, 2023 and 2022; 32,490,119 and 23,129,953 shares issued and outstanding as of december 31, 2023 and 2022, respectively | 89,000 | |||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value, 100,000,000 shares authorized at september 30, 2023 and december 31, 2022; 30,854,778 and 23,129,953 shares issued and outstanding as of september 30, 2023 and december 31, 2022, respectively | 84,000 | |||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value, 100,000,000 shares authorized at june 30, 2023 and december 31, 2022; 23,498,617 and 23,129,953 shares issued and outstanding as of june 30, 2023 and december 31, 2022, respectively | 64,000 | |||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value, 100,000,000 shares authorized at march 31, 2023 and december 31, 2022; 23,440,521 and 23,129,953 shares issued and outstanding as of march 31, 2023 and december 31, 2022, respectively | 64,000 | |||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value; 100,000,000 shares authorized at december 31, 2022 and 2021; 23,129,953 and 22,462,995 shares issued and outstanding as of december 31, 2022 and 2021, respectively | 63,000 | |||||||||||||||||||||||||||
| total shareholders' (deficit) equity | -89,361,000 | |||||||||||||||||||||||||||
| total liabilities and shareholders' (deficit) equity | 135,619,000 | |||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value, 100,000,000 shares authorized at september 30, 2022 and december 31, 2021; 23,011,324 and 22,462,995 shares issued and outstanding as of september 30, 2022 and december 31, 2021, respectively | 63,000 | |||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value, 100,000,000 shares authorized at june 30, 2022 and december 31, 2021; 22,727,891 and 22,462,995 shares issued and outstanding as of june 30, 2022 and december 31, 2021, respectively | 62,000 | |||||||||||||||||||||||||||
| prepaid expense and other current assets | 9,275,000 | 7,476,000 | 6,113,000 | 5,308,000 | ||||||||||||||||||||||||
| right of use asset | 945,000 | 1,180,000 | 1,418,000 | 1,653,000 | 1,901,000 | 2,158,000 | 2,652,000 | 3,011,000 | 3,433,000 | 3,735,000 | ||||||||||||||||||
| accounts payable and accrued expense | 9,936,000 | 11,062,000 | 10,342,000 | |||||||||||||||||||||||||
| employee related accrued expense | 5,146,000 | 6,476,000 | 6,773,000 | |||||||||||||||||||||||||
| long-term lease liability | 277,000 | 616,000 | 922,000 | 1,201,000 | 1,497,000 | 1,748,000 | 1,994,000 | 2,268,000 | 2,604,000 | 1,749,000 | 1,943,000 | 2,184,000 | ||||||||||||||||
| shareholders' equity: | ||||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value; 100,000,000 shares authorized at march 31, 2022 and december 31, 2021; 22,682,221 and 22,462,995 shares issued and outstanding as of march 31, 2022 and december 31, 2021, respectively | 62,000 | |||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value; 100,000,000 shares authorized at december 31, 2021 and 2020; 22,462,995 and 22,167,791 shares issued and outstanding as of december 31, 2021 and 2020, respectively | 61,000 | |||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value; 100,000,000 shares authorized at september 30, 2021 and december 31, 2020; 22,404,845 and 22,167,791 shares issued and outstanding as of september 30, 2021 and december 31, 2020, respectively | 61,000 | |||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value; 100,000,000 shares authorized at june 30, 2021 and december 31, 2020; 22,354,533 and 22,167,791 shares issued and outstanding as of june 30, 2021 and december 31, 2020, respectively | 61,000 | |||||||||||||||||||||||||||
| inventory | 3,331,000 | 1,964,000 | 1,346,000 | 1,125,000 | 316,000 | |||||||||||||||||||||||
| ordinary shares, nis 0.01 par value; 100,000,000 shares authorized at march 31, 2021 and december 31, 2020; 22,280,394 and 22,167,791 shares issued and outstanding as of march 31, 2021 and december 31, 2020, respectively | 61,000 | |||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value; 100,000,000 shares authorized at december 31, 2020 and 2019; 22,167,791 and 21,026,184 shares issued and outstanding as of december 31, 2020 and 2019, respectively | 60,000 | |||||||||||||||||||||||||||
| liabilities and shareholder's equity | ||||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value; 100,000,000 shares authorized at september 30, 2020 and december 31, 2019; 22,071,432 and 21,026,184 shares issued and outstanding as of september 30, 2020 and december 31, 2019, respectively | 60,000 | |||||||||||||||||||||||||||
| total shareholders’ equity | 120,527,000 | 142,660,000 | 150,454,000 | 180,302,000 | 210,916,000 | 224,779,000 | 239,591,000 | 90,094,000 | 68,515,000 | |||||||||||||||||||
| total liabilities and shareholders’ equity | 139,893,000 | 161,077,000 | 166,929,000 | 202,388,000 | 226,753,000 | 238,566,000 | 252,052,000 | 103,559,000 | 75,550,000 | |||||||||||||||||||
| non-current assets | ||||||||||||||||||||||||||||
| total current liabilities | 16,423,000 | 14,207,000 | 19,482,000 | 14,088,000 | 11,844,000 | 10,277,000 | 13,465,000 | 7,035,000 | ||||||||||||||||||||
| shareholders’ equity: | ||||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value; 100,000,000 shares authorized at june 30, 2020 and december 31, 2019; 22,001,296 and 21,026,184 shares issued and outstanding as of june 30, 2020 and december 31, 2019, respectively | 60,000 | |||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value; 100,000,000 shares authorized at march 31, 2020 and december 31, 2019; 21,212,940 and 21,026,184 shares issued and outstanding as of march 31, 2020 and december 31, 2019, respectively | 58,000 | |||||||||||||||||||||||||||
| non-current liability: | ||||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value; 100,000,000 shares authorized at december 31, 2019 and 2018; 21,026,184 and 16,214,883 shares issued and outstanding as of december 31, 2019 and 2018, respectively | 57,000 | |||||||||||||||||||||||||||
| total non-current liabilities | 1,749,000 | 1,943,000 | 2,184,000 | |||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value; 100,000,000 shares authorized at september 30, 2019 and december 31, 2018; 20,944,250 and 16,214,883 shares issued and outstanding as of september 30, 2019 and december 31, 2018, respectively | 57,000 | |||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value; 100,000,000 shares authorized at june 30, 2019 and december 31, 2018; 20,849,515 and 16,214,883 shares issued and outstanding as of june 30, 2019 and december 31, 2018, respectively | 57,000 | |||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value; 100,000,000 shares authorized at march 31, 2019 and december 31, 2018; 20,758,348 and 16,214,883 shares issued and outstanding as of march 31, 2019 and december 31, 2018, respectively | 56,000 | |||||||||||||||||||||||||||
| short-term investments | 36,001,000 | |||||||||||||||||||||||||||
| deferred revenues | 650,000 | |||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value; 100,000,000 shares authorized at december 31, 2018 and 2017; 16,214,883 and 13,751,390 shares issued and outstanding as of december 31, 2018 and 2017, respectively | 44,000 | |||||||||||||||||||||||||||
| proceeds from exercise of warrants for preferred shares | ||||||||||||||||||||||||||||
| non-current liabilities | ||||||||||||||||||||||||||||
| warrants for preferred shares | ||||||||||||||||||||||||||||
| ordinary shares, nis 0.01 par value; 100,000,000 and 17,600,000 shares authorized at december 31, 2017 and 2016, respectively; 13,751,390 and 2,305,743 shares issued and outstanding as of december 31, 2017 and 2016, respectively | 37,000 | |||||||||||||||||||||||||||
| series a and a-1 preferred shares, nis 0.01 par value: 0 and 14,400,000 shares authorized at december 31, 2017 and 2016, respectively; 0 and 5,193,427 shares issued and outstanding at december 31, 2017 and 2016, respectively |
We provide you with 20 years of balance sheets for UroGen Pharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of UroGen Pharma. Explore the full financial landscape of UroGen Pharma stock with our expertly curated balance sheets.
The information provided in this report about UroGen Pharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.